{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056886","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.252126+00:00","generated_at":"2026-06-02T06:45:15.328856+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ALX Oncology Q1 net loss widens to $35.6M; evorpacept B-NHL data shows 83% CRR","bullets":["GAAP net loss $35.6M ($0.71/sh) vs $30.2M ($0.74/sh) in Q1 2023; non-GAAP loss $28.5M vs $23.8M.","Cash & investments $184.5M as of Mar 31; subsequent ATM raised ~$26.2M net; runway into Q1 2026.","Evorpacept + R2 in R/R B-NHL IST: ORR 94%, CRR 83% (historical R2 CRR 34%) in 20 patients.","Upcoming milestones: ASPEN-07 data at ASCO June 2; ASPEN-06 top line July 2024; Phase 3 init Q4 2024.","Appointed Allison Dillon, Ph.D., as Chief Business Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056886","json":"https://secwatch.observer/filing/0000950170-24-056886.json","markdown":"https://secwatch.observer/filing/0000950170-24-056886.md","text":"https://secwatch.observer/filing/0000950170-24-056886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024056886/0000950170-24-056886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024056886/alxo-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:45:15.328856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d461c54be99710fb8a728616f2ebb17f593937fa","claim":"ALX ONCOLOGY HOLDINGS INC reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, ALX Oncology Holdings Inc. (the \"Company\"), issued a press release announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017024056886/0000950170-24-056886-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}